Your session is about to expire
← Back to Search
Blinatumomab for Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Study Summary
This trial is looking at whether a drug called blinatumomab is safe to use in patients who have had a stem cell transplant to treat leukemia or non-Hodgkin's lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 111 Patients • NCT02393859Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have high-risk Pre-B ALL in my first complete remission or am in my second or later complete remission.I haven't had chemotherapy or radiotherapy in the last 2 weeks.I have had severe acute or active severe chronic graft-versus-host disease.I weigh less than 45 kg.I am currently being treated for another cancer.I have been on immunosuppressants for GVHD within the last 4 weeks.I have a significant brain or nervous system condition.I have HIV or chronic hepatitis B or C.I was treated with blinatumomab and my leukemia cells still have CD19.I can take care of myself and perform daily activities.My organs are not functioning properly.My bone marrow transplant from a donor did not work.I have been treated with blinatumomab without severe side effects.My condition worsened after a transplant.I have Ph-positive ALL and cannot receive TKI maintenance after a transplant.I do not have any ongoing serious infections or illnesses.I have active or untreated disease in my brain or testes.I am 60-180 days post-transplant with no signs of my disease getting worse.I have undergone several treatments to reach remission.I have NHL and had a transplant that didn't fully replace my bone marrow.I am on maintenance therapy after a transplant.I am 18 years old or older.
- Group 1: Post-alloHSCT Maintenance
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide a comprehensive overview of the research done with Blinatumomab?
"Presently, 586 trials for the Blinatumomab drug are in progress. Of those studies, 146 have reached Phase 3. The primary study location is Joliet, Illinois; however, these investigations have been conducted at 19 424 sites around the world."
Are there any slots still available for potential participants in this trial?
"Affirmative, the details on clinicaltrials.gov confirm that this trial is actively accruing participants. This research project was initially posted online in September of 2017 and has been refreshed most recently on May 19th 2022."
What is the cap on participants in this clinical research?
"Affirmative, clinicaltrials.gov has outlined that this trial is actively seeking participants. It was first uploaded to the website on September 5th 2017 and most recently modified on May 19th 2022. The two locations involved in recruiting require a combined total of 64 patients for completion."
What are the predominant applications of Blinatumomab?
"Blinatumomab is an effective treatment for ophthalmia, sympathetic and a few other conditions such as branch retinal vein occlusion, eye inflammation, and macular edema."
Share this study with friends
Copy Link
Messenger